Finanzen von Medicus Pharma Ltd (MDCX)MDCXMedicus Pharma Ltd

Evaluating the bottom line, Medicus Pharma Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -7631.06%, provide a clear picture of how effectively MDCX converts its operational activities into shareholder value.

In the context of the broader market, MDCX competes directly with industry leaders such as CVKD and HLSQ. With a market capitalization of $3.61M, it holds a significant position in the sector. When comparing efficiency, MDCX's gross margin of N/A stands against CVKD's N/A and HLSQ's 29.22%. Such benchmarking helps identify whether Medicus Pharma Ltd is trading at a premium or discount relative to its financial performance.

Medicus Pharma has reported consistent financial losses, with a net income loss of $11.62 million in Q2 2026, which is an 89% increase year-over-year. The EPS has also worsened from -0.43 to -0.21 in the same period, indicating deteriorating financial health.